AS Watson Weighs Delay to Autumn London Dual Listing as Superdrug Owner Reads Market Conditions

The Quick Take

• Hong Kong-based AS Watson, owner of Superdrug, is considering postponing its planned autumn 2026 dual listing on the London Stock Exchange
• AS Watson had been targeting the London Stock Exchange for a dual listing to raise capital from its health and beauty retail operations
• The potential delay signals ongoing uncertainty about London's competitiveness as a capital-raising venue for large Asian consumer businesses

AS Watson's possible delay of its planned London Stock Exchange dual listing is a significant signal about current attractiveness of London as a capital-raising venue for Asian consumer conglomerates. The Hong Kong-based health and beauty retail giant — which owns Superdrug in the UK and Ireland, Watsons across Asia, and Kruidvat in the Netherlands — had been targeting an autumn 2026 IPO as part of a broader capital markets strategy. The potential delay, reported by the Financial Times, reflects ongoing investor hesitation about UK retail sector valuations and broader questions about London's competitiveness against New York and Hong Kong for large-cap consumer business listings.

The market implication of an AS Watson IPO delay extends beyond the company itself. London's equity market has been managing a multi-year perception challenge as a listing destination for consumer and retail businesses, with several high-profile companies choosing New York or Amsterdam over London. A delay by a strategically significant Asian conglomerate reinforces that narrative and potentially creates capital market headwinds for other APAC companies evaluating London dual listings. For CK Hutchison Holdings, AS Watson's controlling parent, a delayed IPO means continued consolidation of the retail business on the balance sheet without the capital release a successful listing would provide. UK retail investors also lose access to a rare consumer health and beauty exposure vehicle.

Key watch points include AS Watson's revised IPO timeline guidance — any indication of a spring 2027 re-filing would reset market expectations for the deal. The broader London Stock Exchange listing competitiveness debate is directly linked to UK government reform proposals aimed at attracting international listings, including proposed dual-class share structure liberalization. The macro variable determining whether the IPO proceeds is consumer discretionary retail valuation multiples in London — if UK equity markets re-rate consumer sector stocks upward in H2 2026 driven by easing inflation and Bank of England rate cuts, AS Watson's listing calculus could shift quickly and meaningfully.

Synthesized from 1 source.